---
figid: PMC8001237__cells-10-00533-g001
figtitle: An overview of various approaches used in myostatin inhibition
organisms:
- NA
pmcid: PMC8001237
filename: cells-10-00533-g001.jpg
figlink: pmc/articles/PMC8001237/figure/cells-10-00533-f001/
number: F1
caption: An overview of various approaches used in myostatin inhibition. Various factors
  and approaches in myostatin inhibition as outlined in  and . Treatments applied
  in clinical trials have been colored yellow. The Smad2/3 intracellular signaling
  pathway downstream the ActRIIB leads to altered gene transcription of muscle regulatory
  factors.
papertitle: 'Antimyostatin Treatment in Health and Disease: The Story of Great Expectations
  and Limited Success.'
reftext: Tue L. Nielsen, et al. Cells. 2021 Mar;10(3):533.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9151005
figid_alias: PMC8001237__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC8001237__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8001237__cells-10-00533-g001.html
  '@type': Dataset
  description: An overview of various approaches used in myostatin inhibition. Various
    factors and approaches in myostatin inhibition as outlined in  and . Treatments
    applied in clinical trials have been colored yellow. The Smad2/3 intracellular
    signaling pathway downstream the ActRIIB leads to altered gene transcription of
    muscle regulatory factors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MSTN
  - GPRASP1
  - WFIKKN2
  - ACVR2B
  - ACVR1B
  - TGFBR1
  - SMAD2
  - SMAD3
  - myostatin
  - LY2495655
  - MYO-029
  - PF-354
  - PF-06252616
  - REGN1033
  - RAP-031, ACE-2494
  - AMG
  - RO7239361
  - ACE-083
  - muscle hypertrophy
---
